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Abstract: Few data are available regarding vertebral fracture risk in
patients treated with corticosteroids including patients with interstitial
lung disease (ILD). The aim of the present study was to identify risk
factors for symptomatic vertebral fracture analyzed in patients with
newly diagnosed autoimmune diseases.
This was an observational cohort study conducted in the National
Hospital Organization-EBM study group from 2006 to 2008. The study
subjects were autoimmune disease patients who were newly treated with
glucocorticoids (GCs). The primary endpoint was the first occurrence of
vertebral fracture diagnosed by x-rays. Cox proportional-hazards
regression was used to determine independent risk factors for vertebral
fracture with covariates including sex, age, comorbidity, laboratory data,
use of immunosuppressants, and dose of GCs. Survival was analyzed
according to the Kaplan–Meier method and assessed by the log-rank test.
Among 604 patients of mean age 59.5 years and mean GC dose
50.4 mg/d (first 1 months), 19 patient (3.1%) had at least 1 symptomatic
vertebral fracture during 1.9 years of follow-up period. Cox regression
model demonstrated that the relative risk for symptomatic vertebral
fracture was independently higher in patient with ILD (hazard ratio
[HR]¼ 2.86, 95% confidence interval [CI]¼ 1.10–7.42, P¼ 0.031) and
in every 10-year increment of the age of disease onset (HR¼ 1.57, 95%
CI¼ 1.09–2.26, P¼ 0.015). Kaplan–Meier analyses demonstrated that
the incidence of vertebral fractures in patients with ILD was significantly
higher in comparison with those without ILD.
Our results indicate a higher risk of vertebral facture in patients with
ILD and elderly patients during the initial GC treatment against auto-o Kawahara, MD, kami, MD,
nd Shigeto Tohma, MD
(Medicine 94(27):e875)
Abbreviations: COPD = chronic obstructive lung disease, GCs =
glucocorticoids, IIPs = idiopathic interstitial pneumonias, ILD =
interstitial lung disease, NHO = National Hospital Organization.
INTRODUCTION
G lucocorticoids (GCs) have been widely used in patientswith autoimmune lung disease, as well as in patients with
interstitial lung disease (ILD).1 Fractures, as a result of osteo-
porosis, are serious complications in patients receiving GCs.2
Several large-scale cross-sectional and meta-analysis have
demonstrated that GCs treatment induced osteoporosis and
increased the risks for vertebral fractures.3 Additionally, many
randomized clinical trial have demonstrated that initiation of
bisphosphonates prevents bone loss and fracture.4 However, it is
unlikely that a definite clinical trial regarding fracture will be
performed for many reasons, including relatively low frequency
of fractures as an outcome and difficulty recruiting enough
eligible patients for a trial to be sufficiently powered.4
Autoimmune diseases appear to be conditions that are
particularly associated with decreased bone mineral density
(BMD) and increased fractures, which may be partly iatrogenic
and preventable.5 There are several potential iatrogenic and
lifestyle contributions to osteoporosis. Iatrogenic factors
include adverse bone-related biochemical effects of corticos-
teroids and immunosuppressant, which have been demonstrated
in animal studies, induce bone resorption, and cause osteoporo-
sis.6 Relevant lifestyle factors may lead to adverse bone effects
including reduced levels of physical activity and bone-related
biochemical effects associated with cigarette smoking and
alcohol consumption.7 Also in subjects with severe autoimmune
diseases, periods of greatly reduced activity during hospitaliz-
ation may lead to accelerated bone loss.8 Additionally, patients
treated with GC may progress bone loss, with very different
types of underlying various autoimmune diseases, relating to
their disease processes and various organ involvements.9 There-
fore, the cohort against various autoimmune diseases patients
treated with GC study should be conducted to determine the
actual incidence of fractures and the preventive effects of
various antiosteoporosis agents under real-world setting. In
the present study, we investigated the risk factors of sympto-
matic vertebral fracture, analyzing the database of cohort studywith recently diagnosed autoimmune




Patients and Study Design
Patients were eligible for the study if they were initially
treated with GCs for a recently diagnosed (within 4 weeks prior
to study entry) autoimmune disease using established criteria.10
The cohort start date was defined as the time of initiation of the
first GC prescription. The autoimmune diseases registered in
this study were as follows: rheumatic diseases—systemic lupus
erythematosus, mixed connective-tissue disease, polymyositis,
dermatomyositis, vasculitis, Behçet disease, systemic sclero-
derma, adult-onset Still disease, Sjögren syndrome, rheumatoid
arthritis, autoimmune bullous diseases, and anaphylactoid pur-
pura; neurological diseases—multiple sclerosis, myasthenia
gravis, and chronic inflammatory demyelinating polyneuropa-
thy; gastrohepatobiliary diseases—ulcerative colitis, auto-
immune hepatitis, autoimmune pancreatitis, and primary
biliary cirrhosis. A diagnosis of ILD was established according
to the criteria of the ATS, including consistent clinical features
and pulmonary function tests, radiographic evidence of inter-
stitial disease, and/or lung histopathology consistent with this
diagnosis.11 All patients were evaluated for ILD using high-
resolution computed tomography (HRCT) scans of their lungs.
Diagnosis of ILD was determined by a panel of ILD expert
clinicians and chest radiologists based on serology, clinical
signs, and HRCT analysis. Connective tissue diseases-ILD
was diagnosed if ILD was found in the presence of rheumatic
disease.12 Primary glomerular diseases include rapidly pro-
gressive glomerulonephritis, chronic glomerulonephritis, and
nephrotic syndrome.
A total of 604 patients with newly diagnosed autoimmune
disease were enrolled between April 1, 2006, and March 31,
2008, and regularly followed concerning the occurrence of GC-
related adverse effects (AEs). The observation period ended on
March 31, 2009.
Ethics Approval
Before implementation of this study, institutional review
board and ethics committee approvals of the protocol and the
consent to participate and publish the study were obtained from
each of the participating patients. The study was approved by
the ethical committees of the NHO central internal review board
(No. 0512014, 2006). Written informed consent was obtained
from each individual.
Data Collection
Data from all participating physicians were entered into the
Japanese National Hospital Organization, Study for Adverse
Effects of Corticosteroid Therapy (J-NHOSAC) database at the
data center of the International Medical Center of Japan in
Tokyo, Japan, via the HOSPnet Internet system.
Data on Study Entry
The past comorbid condition of each patient was reviewed
by each of the principle physicians. These conditions included
renal, neurological, endocrine, cardiovascular, and pulmonary
diseases as well as cancer and stroke. In addition, the incidences
of specific conditions, including preexisting pulmonary tuber-
culosis (TB), hepatitis viral infection (hepatitis B virus, hepatitis
C virus), diabetes, hyperlipidemia, arrhythmia, and perform-
Migita et alance status (Karnofsky score), were assessed. The physicians
also provided information on smoking or drinking habits and
history of TB.
2 | www.md-journal.comOutcome Variables
At the start of the study, standardized lists were used to
document AEs, which were classified using the System Organ
Class of the Medical Dictionary for Regulatory Activities
(MedDRA; version 11.1). Each patient received structured
medical interview, including symptoms suggesting vertebral
fractures such as back pain, or lumbago and performance status
assessed by Karnofsky score. All physicians documented epi-
sodes of GC-related AEs requiring medical care and death
certificates and the causes of deaths that occurred during the
follow-up periods. Patients were followed up every 3 months by
the chief physician for each of the NHO hospitals, who collected
clinical findings (disease activity, severity, performance status,
blood pressure, and body weight) and laboratory data (complete
blood cell count, biochemistry, and urinalysis). The telephone
interview concerning the health assessment and the presence of
GCs-related AEs was conducted against few patients who were
moved or transferred to another hospital at the end of the cohort.
However, overall outcome was not available from 2 patients (2/
133, 1.5%) at the end of the study.
Symptomatic Vertebral Fracture
The primary endpoint was the first occurrence of a diag-
nosed symptomatic vertebral fracture. When symptoms sugges-
tive of vertebral fracture occurred, patients underwent
radiography according to the standardized protocol defined
in this study. Symptomatic vertebral fracture was defined as
vertebral deformity with a clinical symptom that was confirmed
by thoracolumbar x-rays in patients with a backache. Lateral
thoracolumbar x-rays of the spine were graded independently by
a radiologist. A symptomatic vertebral fracture was defined as
vertebral deformity that was confirmed by lateral thoracolum-
bar radiography in patients with sudden severe backache.
Vertebral deformity was assessed semiquantitatively by method
similar to that described by Genant et al,13 and deformity was
defined to be present if there was >20% reduction in anterior,
middle, or posterior vertebral height.
Follow-Up Data
Patients were followed up every 3 months by the chief
physician for each of the NHO hospitals, who collected clinical
findings (disease activity, severity, performance status, blood
pressure, and body weight) and laboratory data (complete blood
cell count, biochemistry, and urinalysis). The telephone inter-
view concerning the health assessment and the presence of GCs-
related AEs was conducted against few patients who were
moved or transferred to another hospital at the end of the cohort.
However, overall outcome was not available from 14 patients
(2.3%) at the end of the study. In statistical analysis, we
excluded these participants without final outcome data.
Medications
Details of GCs, immunosuppressants, and biologics were
recorded at each visit, including the route of administration and
dose. We categorized GC exposure according to the mean daily
dose throughout the follow-up period for each patient. We
calculated ‘‘dose equivalents’’ of prednisolone as follows:
1 mg of prednisolone¼ 5 mg of cortisone¼ 4 mg of hydrocor-
Medicine  Volume 94, Number 27, July 2015tisone¼ 1 mg of prednisone¼ 0.8 mg of triamcinolone¼
0.8 mg of methylprednisolone¼ 0.15 mg of dexamethasone¼
0.15 mg of betamethasone.14
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Statistical Analysis
Qualitative variables were compared using the x2 test (or
Medicine  Volume 94, Number 27, July 2015Fisher exact test when appropriate), and quantitative variables
were compared using the Mann–Whitney U test. The incidence
rate of fracture was calculated as the number of fractures per
TABLE 1. Baseline Characteristics of the 604 Patients With Autoi
AOSD¼ adult-onset Still disease, CIDP¼ chronic inflammatory demyelinat
cerebrovascular accident, MCTD¼mixed connective-tissue disease, PBC¼
expressed as mean  standard deviation or number (percentage).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.1000 patient-years (PY). We identified the risk factors of
vertebral fracture by univariate and multivariate Cox-pro-
Glucocorticoid and Vertebral Fractureportional hazard models analysis. The variables included in
the analysis were age, sex, types of primary autoimmune
diseases, comorbidities (diabetes, renal diseases, cardiovascular
mmune Diseases Treated With Glucocorticoid
ing polyneuropathy, CKD¼ chronic kidney disease, CVA¼ cerebrovas-
primary biliary cirrhosis, SLE¼ systemic lupus erythematosus. Data are
www.md-journal.com | 3
TABLE 2. Baseline Clinical and Demographic of Primary Disease Group
ea
Migita et al Medicine  Volume 94, Number 27, July 2015diseases, and ILDs), medications (average dose of GC, the use
of immunosuppressive agents), and performance status (Kar-
nofsky score). Factors included in the Cox-proportional multi-
variate hazard model were those associated with the status (case
or control) of univariate analysis with a significance level of
P< 0.20. Both univariate and multivariate analyses were per-
formed, using the occurrence of at least 1 vertebral fractures
during the follow-up period as the outcome. Results are
expressed as odds ratios with 95% confidence intervals (95%
CIs). Survival, related to follow-up time, was analyzed using the
Kaplan–Meier method and compared using the log-rank test.
Two-sided P values <0.05 were considered statistically signifi-
cant. The analysis was conducted using SAS (version 9.1; SAS
Institute, Cary, NC).
RESULTS
Clinical Characteristics of the Study Population
The baseline characteristics are shown in Table 1. A total
of 604 patients with newly diagnosed autoimmune diseases
BMI¼ body mass index, PY¼ patient-years. Data are expressed as minitially treated with GCs from 51 hospitals were enrolled in the
J-NHOSAC registry between April 2006 and March 2008. The
analysis was performed on all patients with a mean follow-up
FIGURE 1. Incidences of symptomatic vertebral fractures according
fractures in each groups of patients stratified according to the perfor
4 | www.md-journal.comperiod of 1.9 0.64 years, for a total of 1105.8 PY. There were
358 (59.3%) females and 246 (40.7%) males, with a mean age of
59.5 16.8 (range 17–94) years. All patients received GCs at
entry and the mean GCs dose for the first month was
50.4 63.1 mg/d. Concomitant immunosuppressive therapies
are summarized in Table 1. Enrolled patients were categorized
into the 5 groups according to the primary autoimmune diseases
(Table 2). There were some variations in the age of the onset of
primary diseases, sex, initial mean dose of GC, performance
status evaluated by Karnofsky score, and the presence of
comorbidity. In patients with idiopathic interstitial pneumonias
(IIPs), the elderly onset of primary disease, higher mean initial
dose of GC, higher comorbidities, and lower performance status
were observed compared to other groups of patients.
Incidence of Vertebral Fracture
Despite a shorter follow-up period, these were newly
observed 19 vertebral fractures. Table 2 shows a comparison
of the incidence of vertebral fracture among patients’ groups.
Among 604 patients, 19 patients (3.1%) had symptomatic
n  standard deviation or number (percentage).vertebral fractures during the follow-up periods (1.8 0.7
years) indicating that the overall incidences of vertebral frac-
tures are 17.3/1000 PY. There were some variations in the
to the performance status. Incidences of symptomatic vertebral
mance status assessed by Karnofsky score.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
frequencies of vertebral fractures in each hospital (3.1 7.3%).
Although there was heterogeneity in patient’s background data
among each group, there were more vertebral fractures in
patients with IIPs. To determine whether vertebral fracture
could be associated with the disability due to the severity of
autoimmune diseases, we evaluated the frequencies of vertebral
fracture according to the performance status in each group of
primary autoimmune diseases. As shown in Figure 1, vertebral
fractures were not exclusively observed in patients with lower
performance status in each group of primary diseases.
Medicine  Volume 94, Number 27, July 2015Risk Factors for Vertebral Fractures
To identify differences in risk factors that contribute to the
development of vertebral fracture, we compared baseline data
TABLE 3. Baseline Clinical and Demographic Vertebral Features
BMI¼ body mass index, CVA¼ cerebrovascular accident, ex¼ ex-sm
expressed as mean  standard deviation or number (percentage). P values
test for quantitative data.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.between patients with vertebral fracture and those without
vertebral fracture (Table 3). Risk factors for vertebral fracture
identified in univariate analysis were shown in Table 4. In
addition to the significant variables identified by univariate
analysis, we also tentatively forced the dose of corticosteroid
into the Cox-proportional hazard model. In multivariate Cox
regression analysis (Table 5), independent predictors of
vertebral fracture were elderly age (hazard ratio [HR]¼ 1.57,
10-years age increment, 95% CI¼ 1.09–2.26) and the presence
of ILD (HR¼ 2.86, 95% CI¼ 1.10–7.42). Of note, neither
mean doses of initial GCs (first 1 month) nor the use of
bisphosphonates were identified as independent predictors for
Glucocorticoid and Vertebral Fracturevertebral fracture. All patients were stratified according to the
use of bisphosphonates and analyzed by multivariate analysis.
Similarly, elderly age and the presence of ILD were isolated as
of All Patients
oker, IgG¼ immunoglobulin G, WBC¼white blood cell. Data are
were calculated with x2 test for qualitative data and Mann–Whitney
www.md-journal.com | 5
TABLE 4. Predictors of Vertebral Features in the COX-Hazard Model (Univariate Analysis)
rat
Migita et al Medicine  Volume 94, Number 27, July 2015independent predictors for vertebral fracture in patients without
the use of bisphosphonates (Table 6).
Patients with vertebral fracture were found to be signifi-
cantly associated with elderly age and the presence of ILD.
Therefore, Kaplan–Meier survival curves were plotted for the
occurrence of the first vertebral fracture stratified by the pre-
sence of ILD and aging. Kaplan–Meier curves for vertebral
fracture-free survival in patients with ILD versus patients with-
out ILD are shown in Figure 2A. Compared to patients without
ILD, the incidence of vertebral fractures was significantly
higher in patients with ILD (P¼ 0.002, log-rank test,
Figure 2A). Similarly, elderly age (>70 years) significantly
affected the vertebral-free survival of the enrolled patients
(P¼ 0.003, log-rank test, Figure 2B).
DISCUSSION
Osteoporosis is a well-known, dose-dependent adverse
effect of GC therapy.15 Patients with autoimmune diseases
CI ¼ confidence interval, ILD¼ interstitial lung disease, OR ¼ oddstreated with GCs are at risk for osteoporosis or bone fracture,16
but the relative contribution of their primary disease, decreased
exercise, and other factors toward vertebral fractures has not
TABLE 5. Predictors of Vertebral Features in the COX-Hazard Mo
ILD¼ interstitial lung disease.
6 | www.md-journal.combeen established. Understanding the relative contribution of
demographic and clinical variables to vertebral fractures in
patients with autoimmune diseases may augment the prediction
of fracture risk in these patients. This multicenter cohort study
looked at the relationship between primary autoimmune dis-
eases and vertebral fracture risk during initial GC treatments.
We evaluated the contribution of clinical and demographic
variables to vertebral fracture in patients with autoimmune
diseases by using NHO cohort database.10 These subjects have
received initial GC treatment against newly diagnosed auto-
immune diseases. Our results revealed that elderly age and ILD
itself are major risk factors for vertebral fracture after GC
treatment. We found a clear relation between ILD and GC-
induced vertebral fractures, which has not been previously
demonstrated.
Autoimmune and inflammatory disorders can cause detri-
mental changes in bone metabolism that lead to osteoporosis
dependent or independent to GC treatments.17 However, the
studies investigating influences of underlying autoimmune
io.disease on GC-induced vertebral fractures were limited.
Although GCs are useful in the treatment of these conditions,
they may cause a serious AE, bone fracture.18 Previous studies
del (Multivariate Analysis)
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 6. Predictors of Vertebral Features in the COX-Hazard Model (Patients Without the Use of Bisphosphonates)
rat
Medicine  Volume 94, Number 27, July 2015 Glucocorticoid and Vertebral Fracturehave suggested a prominent effect of chronic obstructive lung
disease (COPD) on the vertebral fracture rate independent of
steroid use.19 McEvoy et al20 reported that the proportion of
CI ¼ confidence interval, ILD¼ interstitial lung disease, OR ¼ oddsCOPD patients with vertebral fractures was 49%, 57%, and 62%
for those receiving no GC, inhaled GC, or oral GC. In addition,
subjects with COPD who had not been treated with GC had a
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.relatively greater reduction in bone loss.21 Although an associ-
ation between GC dose and vertebral fracture risk was not
demonstrated in the present study, our data suggest that
vertebral fractures are highly prevalent in patients with ILD,
once the GC therapy is initialed. Furthermore, patients with
respiratory diseases may have an increased risk for osteoporosis
because of the sedentary lifestyle imposed by their pulmonary
insufficiency.22 Therefore, patients with chronic lung diseases
are at greater risk for osteoporosis and sustaining fractures than
the general population, irrespective of GC use.
GCs are involved in the dynamics of bone and calcium
metabolism.23 The inhibitory effects of GCs on bone growth are
likely to be secondary to inhibition of bone formation with
decreased synthesis of RNA, collagen, bone matrix com-
ponents, and bone proteins.24 GCs have a greater effect on
trabecular bone than on cortical bone and as a result cause
fractures in vertebrae.25 Hypoxia has negative effect on bone
mineralization,26 but whether the association is mediated
through the degree of arterial oxygen saturation is unknown.
Patients with COPD are at increased risk of osteoporosis and
related fracture.20 This increased risk seems to be because of
risk factors, such as smoking, advanced age, physical inactivity,
and chronic inflammatory state.27 However, whether patients
with ILDs have increased risk of osteoporosis or fracture under
GC treatment had not been addressed. Patients with ILD tend to
develop chronic hypoxia. The risks for vertebral fractures in
chronic pulmonary diseases secondary to GC use may be greater
than those in other diseases requiring GC. Increased ILD
severity could be a potential confounding factor, as decreased
physical activity may decrease bone loss. However, ILD sever-
ity is unlikely to be an important confounder as there was no
difference in patients’ performance status evaluated by Kar-
nofsky score between ILD patients with or without
io.vertebral fracture.
Our results highlight the lack of attention given to the
prevention of GC-induced vertebral fracture on focusing the
FIGURE 2. (A) Kaplan–Meier curves of fracture-free survival of
patients with or without ILD. Curves are stratified by the presence
or absence of ILD. Statistically significant differences were
observed between patients with or without ILD (P<0.0001,
log-rank test). (B) Kaplan–Meier curves of fracture-free survival
of patients stratified by aging. Curves are stratified by elderly age
(70 years old vs 70 years old). Statistically significant differences
were observed between these 2 groups (P<0.0001, log-rank
test). ILD ¼ interstitial lung disease.
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primary diseases. Despite the well-known association of GCs
and bone fractures, few studies addressed according to the
primary diseases. Recent studies have demonstrated that GC-
induced bone fracture can be effectively prevented by the
established treatment regimens.28 Interestingly, patients with
other underlying autoimmune diseases were at lower risk for
vertebral fracture compared to those with ILD indicating that
vertebral fracture could be a frequent complication in patients
with ILD.
Our study has several limitations. Although the correlation
between BMD and GC-induced fracture risk has been demon-
strated,2 we have no data on BMD in the study subjects.
Recently, it has been known that vertebral fracture associated
with GC therapy often is asymptomatic.29 As the clinical
observation of the condition initiated the diagnostic procedure
for symptomatic vertebral fracture in the present study, the
fracture incidences observed might be less than the degree of
actual occurrence. The information concerning previous
vertebral or fragility fractures was lacking in this study. The
follow-up periods (mean 1.9 years) were relatively short in this
study. Lifestyle risk factors, such as calcium/vitamin D supple-
ments and the menopause status of individual patients, were not
available in this study. The vitamin D levels have been proven
to be related with vertebral fracture in various autoimmune
diseases.30 However, these information were not available in
this study. It is recommended that patients with idiopathic
pulmonary fibrosis (IPF) should not be treated with corticos-
teroid monotherapy according to American Thoracic Society
and the European Respiratory Society guidelines.31 However,
some patients with IPF were treated with corticosteroid mono-
therapy. Also, the ethnic background of the patients in our study
is predominantly Asian, which precludes the generalizability of
the results to other ethnic populations. The number of subjected
patients was relatively small and there was a deal of hetero-
geneity in the patient’s demographic data according to the
primary diseases.
In conclusion, we have shown that age and the presence of
ILD are important and independent risk factors for vertebral
fractures in patients newly treated with corticosteroids. Further
studies should examine whether bisphosphonate or other treat-
ment in ILD patients also produce consequent reduction in
vertebral fractures noted in these patients. Given the high rate of
vertebral fractures noted in ILD patients, regular screening for
vertebral fractures and BMD should be considered.
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